Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Norman Hollenberg

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Phenomena

Renal Circulation

Chemicals & Drugs

Anatomy

Procedures

Sodium-Restricted Diet

Concepts & Ideas

Drug Dose-Response Relationship

Physiology

Glomerular Filtration Rate

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
41
Fisher, Naomi
24
Price, Deborah
17
Graves, Steven
15
Lansang, Cecilia
11
Williams, Gordon
10
Tao, QF
10
Laffel, Lori
9
Moore, Thomas
8
Osei, Suzette
7
Stevanovic, Radomir
6
Williams, Gordon
5
Seely, Ellen
5
Jeunemaitre, Xavier
4
Conlin, Paul
4
De'Oliveira, JM

Sign-in to see all Coauthors

Publications

TOP 3
Sarna M A; Hollenberg N K; Seely E W; Ahmed S B
Oral contraceptive progestins and angiotensin-dependent control of the renal circulation in humans.
Parving Hans-Henrik; Persson Frederik; Lewis Julia B; Lewis Edmund J; Hollenberg Norman K
[Aliskiren combined with losartan in type 2-diabetes and nephropathy - secondary publication]
Corti Roberto; Flammer Andreas J; Hollenberg Norman K; Lüscher Thomas F
Cocoa and cardiovascular health.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Norman Hollenberg (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Sarna M A; Hollenberg N K; Seely E W; Ahmed S B
Oral contraceptive progestins and angiotensin-dependent control of the renal circulation in humans.
Journal of human hypertension 2009;23(6):407-14.
2009: Parving Hans-Henrik; Persson Frederik; Lewis Julia B; Lewis Edmund J; Hollenberg Norman K
[Aliskiren combined with losartan in type 2-diabetes and nephropathy - secondary publication]
Ugeskrift for laeger 2009;171(11):881-4.
2009: Corti Roberto; Flammer Andreas J; Hollenberg Norman K; Lüscher Thomas F
Cocoa and cardiovascular health.
Circulation 2009;119(10):1433-41.
2008: Krop Manne; Garrelds Ingrid M; de Bruin René J A; van Gool Jeanette M G; Fisher Naomi D L; Hollenberg Norman K; Jan Danser A H
Aliskiren accumulates in Renin secretory granules and binds plasma prorenin.
Hypertension 2008;52(6):1076-83.
2008: Hollenberg Norman K
Influencing the natural history of hypertension: is it the blood pressure achieved, the drug, or the drug dose?
Journal of hypertension 2008;26(8):1527-32.
2008: Fisher Naomi D L; Jan Danser A H; Nussberger J; Dole William P; Hollenberg Norman K
Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans.
Circulation 2008;117(25):3199-205.
2008: Parving Hans-Henrik; Persson Frederik; Lewis Julia B; Lewis Edmund J; Hollenberg Norman K;
Aliskiren combined with losartan in type 2 diabetes and nephropathy.
The New England journal of medicine 2008;358(23):2433-46.
2008: Sorond Farzaneh A; Lipsitz Lewis A; Hollenberg Norman K; Fisher Naomi Dl
Cerebral blood flow response to flavanol-rich cocoa in healthy elderly humans.
Neuropsychiatric disease and treatment 2008;4(2):433-40.
2007: Hollenberg Norman K
Mortality in type 2 diabetes mellitus.
Journal of hypertension 2007;25(12):2381-2.
2007: Hollenberg Norman K; Fisher Naomi D L
Is it the dark in dark chocolate?
Circulation 2007;116(21):2360-2.
2007: Hollenberg Norman K
Renin inhibition: what are the clinical perspectives?
Seminars in nephrology 2007;27(5):511-8.
2007: Hollenberg Norman K; Parving Hans-Henrik; Viberti Giancarlo; Remuzzi Giuseppe; Ritter Susan; Zelenkofske Steven; Kandra Albert; Daley William L; Rocha Ricardo
Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus.
Journal of hypertension 2007;25(9):1921-6.
2007: Ahmed Sofia B; Fisher Naomi D L; Hollenberg Norman K
Gender and the renal nitric oxide synthase system in healthy humans.
Clinical journal of the American Society of Nephrology : CJASN 2007;2(5):926-31.
2007: Stevanovic Radomir D; Fisher Naomi D L; Lansang Cecilia M; Freeman Katherine D; Hollenberg Norman K
Short- and long-term glycaemic control and the state of the renin system in type 1 diabetes mellitus.
Journal of the renin-angiotensin-aldosterone system : JRAAS 2007;8(2):85-92.
2007: Hollenberg Norman K
A brief response to Sealey and Laragh.
Journal of the renin-angiotensin-aldosterone system : JRAAS 2007;8(2):53.
2007: Perlstein Todd S; Gerhard-Herman Marie; Hollenberg Norman K; Williams Gordon H; Thomas Abraham
Insulin induces renal vasodilation, increases plasma renin activity, and sensitizes the renal vasculature to angiotensin receptor blockade in healthy subjects.
Journal of the American Society of Nephrology : JASN 2007;18(3):944-51.
2007: Hollenberg N K
Obesity and the kidney: why is the kidney at risk?
Kidney international 2007;71(3):187-8.
2007: Hollenberg Norman K
The renin system: is direct renin inhibition different from blockade at the AT1 receptor or the ACE step?
Reviews in cardiovascular medicine 2007;8 Suppl 2():S7-13.
2007: Bayard Vicente; Chamorro Fermina; Motta Jorge; Hollenberg Norman K
Does flavanol intake influence mortality from nitric oxide-dependent processes? Ischemic heart disease, stroke, diabetes mellitus, and cancer in Panama.
International journal of medical sciences 2007;4(1):53-8.
2006: Hollenberg Norman K
Organ systems dependent on nitric oxide and the potential for nitric oxide-targeted therapies in related diseases.
Journal of clinical hypertension (Greenwich, Conn.) 2006;8(12 Suppl 4):63-73.
2006: Stankovic Ana R; Fisher Naomi D L; Hollenberg Norman K
Prorenin and angiotensin-dependent renal vasoconstriction in type 1 and type 2 diabetes.
Journal of the American Society of Nephrology : JASN 2006;17(12):3293-9.
2006: Hollenberg Norman K; Epstein Murray
Renin angiotensin system blockade and nephropathy: why is it being called into question, and should it be?
Clinical journal of the American Society of Nephrology : CJASN 2006;1(5):1046-8.
2006: Lansang M Cecilia; Coletti Caroline; Ahmed Sofia; Gordon Michael S; Hollenberg Norman K
Effects of the PPAR-gamma agonist rosiglitazone on renal haemodynamics and the renin-angiotensin system in diabetes.
Journal of the renin-angiotensin-aldosterone system : JRAAS 2006;7(3):175-80.
2006: Fisher Naomi D L; Hollenberg Norman K
Aging and vascular responses to flavanol-rich cocoa.
Journal of hypertension 2006;24(8):1575-80.
2006: Hollenberg Norman K
The influence of dietary sodium on blood pressure.
Journal of the American College of Nutrition 2006;25(3 Suppl):240S-246S.
2006: Halpern Michael T; Khan Zeba M; Schmier Jordana K; Burnier Michel; Caro J Jaime; Cramer Joyce; Daley William L; Gurwitz Jerry; Hollenberg Norman K
Recommendations for evaluating compliance and persistence with hypertension therapy using retrospective data.
Hypertension 2006;47(6):1039-48.
2006: Hollenberg Norman K; Williams Gordon H
Nonmodulation and essential hypertension.
Current hypertension reports 2006;8(2):127-31.
2006: Hollenberg Norman K
Diabetes, nephropathy, and the renin system.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 2006;24(1):S81-7.
2006: Azizi Michel; Webb Randy; Nussberger Juerg; Hollenberg Norman K
Renin inhibition with aliskiren: where are we now, and where are we going?
Journal of hypertension 2006;24(2):243-56.
2006: Hollenberg Norman K
Omission of drug dose information.
Archives of internal medicine 2006;166(3):368; author reply 368-9.
2006: Schroeter Hagen; Heiss Christian; Balzer Jan; Kleinbongard Petra; Keen Carl L; Hollenberg Norman K; Sies Helmut; Kwik-Uribe Catherine; Schmitz Harold H; Kelm Malte
(-)-Epicatechin mediates beneficial effects of flavanol-rich cocoa on vascular function in humans.
Proceedings of the National Academy of Sciences of the United States of America 2006;103(4):1024-9.
2006: Fisher Naomi D L; Sorond Farzaneh A; Hollenberg Norman K
Cocoa flavanols and brain perfusion.
Journal of cardiovascular pharmacology 2006;47 Suppl 2():S210-4.
2006: McCullough Marjorie L; Chevaux Kati; Jackson Lilian; Preston Mack; Martinez Gregorio; Schmitz Harold H; Coletti Caroline; Campos Hannia; Hollenberg Norman K
Hypertension, the Kuna, and the epidemiology of flavanols.
Journal of cardiovascular pharmacology 2006;47 Suppl 2():S103-9; discussion 119-21.
2005: Hollenberg Norman K
The role of beta-blockers as a cornerstone of cardiovascular therapy.
American journal of hypertension 2005;18(12 Pt 2):165S-168S.
2005: Hollenberg Norman K
The road ahead with beta-blockers: expanding treatment options in cardiovascular disease.
American journal of hypertension 2005;18(12 Pt 2):163S-164S.
2005: Hollenberg Norman K; Mohres Erin; Meinking Terri; Preston Mack; Crespo Benny; Rivera Alicio; Jackson Lillian; Martinez Gregorio; Loken Won Mee
Stress and blood pressure in Kuna Amerinds.
Journal of clinical hypertension (Greenwich, Conn.) 2005;7(12):714-20.
2005: Hollenberg Norman K
Is there a pharmacologic basis for combination renin axis blockade?
Kidney international 2005;68(6):2901-3.
2005: Ahmed Sofia B; Fisher Naomi D L; Stevanovic Radomir; Hollenberg Norman K
Body mass index and angiotensin-dependent control of the renal circulation in healthy humans.
Hypertension 2005;46(6):1316-20.
2005: Hollenberg Norman K;
Renin report: spotlight on Renin: therapeutic opportunities for Renin inhibitors.
Journal of the renin-angiotensin-aldosterone system : JRAAS 2005;6(2):107-9.
2005: Stevanovic Radomir D; Price Deborah A; Lansang M Cecilia; Fisher Naomi Dl; Laffel Lori Mb; Hollenberg Norman K
Renin release in response to Renin system blockade: activation of the Renin system in type 1 diabetes mellitus.
Journal of the renin-angiotensin-aldosterone system : JRAAS 2005;6(2):78-83.
2005: Ahmed Sofia B; Hovind Peter; Parving Hans-Henrik; Rossing Peter; Price Deborah A; Laffel Lori M; Lansang M Cecilia; Stevanovic Radomir; Fisher Naomi D L; Hollenberg Norman K
Oral contraceptives, angiotensin-dependent renal vasoconstriction, and risk of diabetic nephropathy.
Diabetes care 2005;28(8):1988-94.
2005: Fisher Naomi D L; Hollenberg Norman K
Flavanols for cardiovascular health: the science behind the sweetness.
Journal of hypertension 2005;23(8):1453-9.
2005: Fisher Naomi D L; Hollenberg Norman K
Renin inhibition: what are the therapeutic opportunities?
Journal of the American Society of Nephrology : JASN 2005;16(3):592-9.
2005: Lansang M Cecilia; Stevanovic Radomir; Price Deborah A; Laffel Lori M B; Hollenberg Norman K
ACE and non-ACE pathways in the renal vascular response to RAS interruption in type 1 diabetes mellitus.
Kidney international 2005;67(3):1033-7.
2004: Hollenberg Norman K
Advanced glycation end-product cross-link breakers. A novel therapeutic pathway for cardiovascular disease.
American journal of hypertension 2004;17(12 Pt 2):21S-22S.
2004: Hollenberg Norman K
Lead exposure and chronic renal failure.
Archives of internal medicine 2004;164(22):2507; author reply 2508-9.
2004: Hollenberg Norman K
Clinical trials report. Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects.
Current hypertension reports 2004;6(5):336.
2004: Perlstein Todd S; Gumieniak Olga; Hopkins Paul N; Murphey Laine J; Brown Nancy J; Williams Gordon H; Hollenberg Norman K; Fisher Naomi D L
Uric acid and the state of the intrarenal renin-angiotensin system in humans.
Kidney international 2004;66(4):1465-70.
2004: Hollenberg Norman K
Literature alert. Endothelial dilatory function predicts individual susceptibility to renal damage in the 5/6 nephrectomized rats.
Current hypertension reports 2004;6(4):251-2.
2004: Gumieniak Olga; Perlstein Todd S; Hopkins Paul N; Brown Nancy J; Murphey Laine J; Jeunemaitre Xavier; Hollenberg Norman K; Williams Gordon H
Thyroid function and blood pressure homeostasis in euthyroid subjects.
The Journal of clinical endocrinology and metabolism 2004;89(7):3455-61.
2004: Epstein Murray; Hollenberg Norman K
Effects of the angiotensin-1 receptor blocker valsartan compared with amlodipine on renal hemodynamics.
American journal of hypertension 2004;17(7):638-9; author reply 639-40.
2004: Hollenberg Norman K
Aldosterone in the development and progression of renal injury.
Kidney international 2004;66(1):1-9.
2004: Cohn Jay N; Quyyumi Arshed A; Hollenberg Norman K; Jamerson Kenneth A
Surrogate markers for cardiovascular disease: functional markers.
Circulation 2004;109(25 Suppl 1):IV31-46.
2004: Hollenberg Norman K
Prognostic value of ambulatory blood pressure recordings in patients with treated hypertension.
Current hypertension reports 2004;6(2):80.
2004: Hollenberg Norman K; Stevanovic Radomir; Agarwal Anupam; Lansang M Cecilia; Price Deborah A; Laffel Lori M B; Williams Gordon H; Fisher Naomi D L
Plasma aldosterone concentration in the patient with diabetes mellitus.
Kidney international 2004;65(4):1435-9.
2004: Aviv Abraham; Hollenberg Norman K; Weder Alan
Urinary potassium excretion and sodium sensitivity in blacks.
Hypertension 2004;43(4):707-13.
2004: Seely Ellen W; Brosnihan K Bridget; Jeunemaitre Xavier; Okamura Kyoko; Williams Gordon H; Hollenberg Norman K; Herrington David M
Effects of conjugated oestrogen and droloxifene on the renin-angiotensin system, blood pressure and renal blood flow in postmenopausal women.
Clinical endocrinology 2004;60(3):315-21.
2004: Aviv Abraham; Hollenberg Norman K; Weder Alan B
Sodium glomerulopathy: tubuloglomerular feedback and renal injury in African Americans.
Kidney international 2004;65(2):361-8.
2004: Hollenberg Norman K
Treatment of the patient with diabetes mellitus and risk of nephropathy: what do we know, and what do we need to learn?
Archives of internal medicine 2004;164(2):125-30.
2003: Hollenberg Norman K
Considerations for management of fluid dynamic issues associated with thiazolidinediones.
The American journal of medicine 2003;115 Suppl 8A():111S-115S.
2003: Fisher Naomi D L; Hughes Meghan; Gerhard-Herman Marie; Hollenberg Norman K
Flavanol-rich cocoa induces nitric-oxide-dependent vasodilation in healthy humans.
Journal of hypertension 2003;21(12):2281-6.
2003: Kosachunhanun Natapong; Hunt Steven C; Hopkins Paul N; Williams Roger R; Jeunemaitre Xavier; Corvol Pierre; Ferri Claudio; Mortensen Richard M; Hollenberg Norman K; Williams Gordon H
Genetic determinants of nonmodulating hypertension.
Hypertension 2003;42(5):901-8.
2003: Hollenberg Norman K
Urinary albumin excretion predicts cardiovascular and non-cardiovascular mortality in general population.
Current hypertension reports 2003;5(5):356-7.
2003: Hollenberg Norman K
A comparison of magnesium sulfate and nimodipine for the prevention of eclampsia.
Current hypertension reports 2003;5(4):288-9.
2003: Hollenberg Norman K
Red wine polyphenols enhance endothelial nitric oxide synthase expression and subsequent nitric oxide release from endothelial cells.
Current hypertension reports 2003;5(4):287-8.
2003: Hollenberg Norman K
Reduced reactivity of renal microvessels to pressure and AngII in fawn-hooded rats.
Current hypertension reports 2003;5(4):286-7.
2003: Hollenberg Norman K
Nephron number in patients with primary hypertension.
Current hypertension reports 2003;5(4):285-6.
2003: Hollenberg Norman K
Reduction of proteinuria; combined effects of receptor blockade and low dose angiotensin-converting enzyme inhibition.
Current hypertension reports 2003;5(4):284-5.
2003: Hollenberg Norman K; Williams Gordon H; Anderson Richard; Akhras Kasem S; Bittman Richard M; Krause Scott L
Symptoms and the distress they cause: comparison of an aldosterone antagonist and a calcium channel blocking agent in patients with systolic hypertension.
Archives of internal medicine 2003;163(13):1543-8.
2003: Hollenberg Norman K
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic.
Current hypertension reports 2003;5(3):183-5.
2003: Hurwitz Shelley; Fisher Naomi D; Ferri Claudio; Hopkins Paul N; Williams Gordon H; Hollenberg Norman K
Controlled analysis of blood pressure sensitivity to sodium intake: interactions with hypertension type.
Journal of hypertension 2003;21(5):951-9.
2003: Hollenberg Norman K
Pivotal role of the renin/protein receptor in angiotensin II production and cellular responses to renin.
Current hypertension reports 2003;5(2):98-9.
2003: Sánchez Ramiro A; Ramos Felipe; Giannone Carlos; Fischer Patricia; Masnatta Lucas; Baglivo Hugo P; Ramírez Agustín J; Hollenberg Norman K
Parallel renal and extremity blood supply abnormalities in nonmodulation: responses to ACE inhibition.
Hypertension 2003;41(4):919-24.
2003: Hollenberg Norman K
Dietary sodium and target organ damage in essential hypertension.
Current hypertension reports 2003;5(1):8.
2003: Hollenberg Norman K; Price Deborah A; Fisher Naomi D L; Lansang M Cecilia; Perkins Bruce; Gordon Michael S; Williams Gordon H; Laffel Lori M B
Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus.
Kidney international 2003;63(1):172-8.
2002: Hollenberg Norman K
Vascular abnormalities and elevated blood pressure in mice lacking adrenomedullin gene.
Current hypertension reports 2002;4(6):414.
2002: Hollenberg Norman K
Defective nitric oxide production and functional renal reserve in patients with type 2 diabetes who have microalbuminuria of African and Asian compared with white origin.
Current hypertension reports 2002;4(6):413; discussion 413-4.
2002: Hollenberg Norman K
A genomic-systems biology map for cardiovascular function.
Current hypertension reports 2002;4(6):412-3.
2002: Hollenberg Norman K
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure.
Current hypertension reports 2002;4(6):411; discussion 412.
2002: Price D A; Lansang M C; Osei S Y; Fisher N D L; Laffel L M B; Hollenberg N K
Type 2 diabetes, obesity, and the renal response to blocking the renin system with irbesartan.
Diabetic medicine : a journal of the British Diabetic Association 2002;19(10):858-61.
2002: Hollenberg Norman K
Angiotensin II suppression in humans by the orally active renin inhibitor aliskiren (SPP100). Comparison with enalapril.
Current hypertension reports 2002;4(4):269-70.
2002: Hollenberg Norman K
Characteristics of patients with uncontrolled hypertension in the United States.
Current hypertension reports 2002;4(4):268; discussion 269.
2002: Hollenberg Norman K
Human hypertension caused by mutations in WNK kinases.
Current hypertension reports 2002;4(4):267.
2002: Price Deborah A; Fisher Naomi D L; Lansang M Cecilia; Stevanovic Radomir; Williams Gordon H; Hollenberg Norman K
Renal perfusion in blacks: alterations caused by insuppressibility of intrarenal renin with salt.
Hypertension 2002;40(2):186-9.
2002: Lansang M Cecilia; Hollenberg Norman K
Renal perfusion and the renal hemodynamic response to blocking the renin system in diabetes: are the forces leading to vasodilation and vasoconstriction linked?
Diabetes 2002;51(7):2025-8.
2002: Hollenberg Norman K
Antihypertensive drug therapy in Saskatchewan.
Current hypertension reports 2002;4(3):179.
2002: Hollenberg Norman K
Genetic versus environmental etiology of the metabolic syndrome among male and female twins.
Current hypertension reports 2002;4(3):178.
2002: Hopkins Paul N; Hunt Steven C; Jeunemaitre Xavier; Smith Barbara; Solorio Daniel; Fisher Naomi D L; Hollenberg Norman K; Williams Gordon H
Angiotensinogen genotype affects renal and adrenal responses to angiotensin II in essential hypertension.
Circulation 2002;105(16):1921-7.
2002: Fisher Naomi D L; Hurwitz Shelley; Jeunemaitre Xavier; Hopkins Paul N; Hollenberg Norman K; Williams Gordon H
Familial aggregation of low-renin hypertension.
Hypertension 2002;39(4):914-8.
2002: Lansang M Cecilia; Osei Suzette Y; Coletti Caroline; Krupinski Janelle; Hollenberg Norman K
Hyperglycaemia-induced intrarenal RAS activation: the contribution of metabolic pathways.
Journal of the renin-angiotensin-aldosterone system : JRAAS 2002;3(1):19-23.
2001: Price D A; Hollenberg N K
Angiotensin receptor blockers in diabetic nephropathy.
Current diabetes reports 2001;1(3):267-74.
2001: Hollenberg N K
Potential of the angiotensin II receptor 1 blocker eprosartan in the management of patients with hypertension or heart failure.
Current hypertension reports 2001;3 Suppl 1():S25-8.
2001: Hollenberg N K
ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure.
Current hypertension reports 2001;3(3):178.
2001: Hollenberg N K
Higher incidence of diabetic nephropathy in type 2 than in type 1 diabetes in early-onset diabetes in Japan.
Current hypertension reports 2001;3(3):177.
2001: Lansang M C; Price D A; Laffel L M; Osei S Y; Fisher N D; Erani D; Hollenberg N K
Renal vascular responses to captopril and to candesartan in patients with type 1 diabetes mellitus.
Kidney international 2001;59(4):1432-8.
2001: Hollenberg N K; Osei S Y; Lansang M C; Price D A; Fisher N D
Salt intake and non-ACE pathways for intrarenal angiotensin II generation in man.
Journal of the renin-angiotensin-aldosterone system : JRAAS 2001;2(1):14-8.
2001: Hollenberg N K; Anzalone D A; Falkner B; Fisher N D; Hopkins P N; Hsueh W; Hutchinson H; Krauss R M; Price D A; Raskin P; Reaven G M
Familial factors in the antihypertensive response to lisinopril.
American journal of hypertension 2001;14(3):218-23.
2001: Price D A; Fisher N D; Osei S Y; Lansang M C; Hollenberg N K
Renal perfusion and function in healthy African Americans.
Kidney international 2001;59(3):1037-43.
2001: Fisher N D; Hollenberg N K
Is there a future for renin inhibitors?
Expert opinion on investigational drugs 2001;10(3):417-26.
2001: Hollenberg N K
A genome-wide search for susceptibility loci to human essential hypertension.
Current hypertension reports 2001;3(1):7-8.
2000: Graves S W; Markides K E; Hollenberg N K
Application of supercritical fluid chromatography to characterize a labile digitalis-like factor.
Hypertension 2000;36(6):1059-64.
2000: Lansang M C; Osei S Y; Price D A; Fisher N D; Hollenberg N K
Renal hemodynamic and hormonal responses to the angiotensin II antagonist candesartan.
Hypertension 2000;36(5):834-8.
2000: Gordon M S; Price D A; Hollenberg N K
Blunted suppression of plasma renin activity in diabetes.
Journal of the renin-angiotensin-aldosterone system : JRAAS 2000;1(3):252-6.
2000: Osei S Y; Price D A; Laffel L M; Lansang M C; Hollenberg N K
Effect of angiotensin II antagonist eprosartan on hyperglycemia-induced activation of intrarenal renin-angiotensin system in healthy humans.
Hypertension 2000;36(1):122-6.
2000: Hollenberg N K; Williams G H; Anderson R
Medical therapy, symptoms, and the distress the cause: relation to quality of life in patients with angina pectoris and/or hypertension.
Archives of internal medicine 2000;160(10):1477-83.
2000: Hollenberg N K; Fisher N D; Price D A; Williams G H
Effect of ACE inhibition on pressor, renal vascular, and adrenal responses to infusion of angiotensin I in normal subjects eating a low-salt diet.
American journal of hypertension 2000;13(5 Pt 1):498-503.
2000: Hollenberg N K
Implications of species difference for clinical investigation: studies on the renin-angiotensin system.
Hypertension 2000;35(1 Pt 2):150-4.
2000: Hollenberg N K
The renin-angiotensin system and cardiovascular disease.
Blood pressure. Supplement 2000;1():5-8.
1999: Tao Q F; Hollenberg N K; Graves S W
Sodium pump inhibition and regional expression of sodium pump alpha-isoforms in lens.
Hypertension 1999;34(5):1168-74.
1999: Price D A; Porter L E; Gordon M; Fisher N D; De'Oliveira J M; Laffel L M; Passan D R; Williams G H; Hollenberg N K
The paradox of the low-renin state in diabetic nephropathy.
Journal of the American Society of Nephrology : JASN 1999;10(11):2382-91.
1999: Fisher N D; Hurwitz S; Ferri C; Jeunemaitre X; Hollenberg N K; Williams G H
Altered adrenal sensitivity to angiotensin II in low-renin essential hypertension.
Hypertension 1999;34(3):388-94.
1999: Hollenberg N K; Rivera A; Meinking T; Martinez G; McCullough M; Passan D; Preston M; Taplin D; Vicaria-Clement M
Age, renal perfusion and function in island-dwelling indigenous Kuna Amerinds of Panama.
Nephron 1999;82(2):131-8.
1999: Price D A; De'Oliveira J M; Fisher N D; Williams G H; Hollenberg N K
The state and responsiveness of the renin-angiotensin-aldosterone system in patients with type II diabetes mellitus.
American journal of hypertension 1999;12(4 Pt 1):348-55.
1999: Hollenberg N K
Review of eprosartan: a new angiotensin II receptor antagonist. Introduction.
Pharmacotherapy 1999;19(4 Pt 2):71S-72S.
1999: Osei S Y; Price D A; Fisher N D; Porter L; Laffel L M; Hollenberg N K
Hyperglycemia and angiotensin-mediated control of the renal circulation in healthy humans.
Hypertension 1999;33(1 Pt 2):559-64.
1999: Hollenberg N K
Pharmacologic interruption of the renin-angiotensin system and the kidney: differential responses to angiotensin-converting enzyme and renin inhibition.
Journal of the American Society of Nephrology : JASN 1999;10 Suppl 11():S239-42.
1998: Graves S W; Tao Q F; Markides K E; Williams G H; Hollenberg N K
A labile sodium pump inhibitor from the peritoneal dialysate of hypertensive renal failure patients: estimates of potency.
Clinical and experimental hypertension (New York, N.Y. : 1993) 1998;20(5-6):611-6.
1998: Porter L E; Hollenberg N K
Obesity, salt intake, and renal perfusion in healthy humans.
Hypertension 1998;32(1):144-8.
1997: Hollenberg N K
Non-insulin-dependent diabetes mellitus, nephropathy, and the renin system.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 1997;15(7):S7-13.
1997: Soszynski P; Ensign A; Graves S W; Hollenberg N K
Specificity of the vascular smooth muscle contractile response to a labile digitalis-like factor in peritoneal dialysate: the influence of potassium.
American journal of hypertension 1997;10(12 Pt 1):1342-8.
1997: Allan D R; Hui K Y; Coletti C; Hollenberg N K
Renin vs. angiotensin-converting enzyme inhibition in the rat: consequences for plasma and renal tissue angiotensin.
The Journal of pharmacology and experimental therapeutics 1997;283(2):661-5.
1997: Soszynski P A; Tao Q F; Hollenberg N K; Graves S W
Tissue-specific regulation of the sodium pump in DOCA-salt hypertension.
American journal of hypertension 1997;10(10 Pt 1):1132-9.
1997: De'Oliveira J M; Price D A; Fisher N D; Allan D R; McKnight J A; Williams G H; Hollenberg N K
Autonomy of the renin system in type II diabetes mellitus: dietary sodium and renal hemodynamic responses to ACE inhibition.
Kidney international 1997;52(3):771-7.
1997: Price D A; De'Oliveira J M; Fisher N D; Hollenberg N K
Renal hemodynamic response to an angiotensin II antagonist, eprosartan, in healthy men.
Hypertension 1997;30(2 Pt 1):240-6.
1997: Soszynski P A; Tao Q F; Krep H H; Hollenberg N K; Graves S W
Renal sodium pump regulation in deoxycorticosterone salt hypertension in the rat.
American journal of hypertension 1997;10(5 Pt 1):525-34.
1997: Fisher N D; Ferri C; Bellini C; Santucci A; Gleason R; Williams G H; Hollenberg N K; Seely E W
Age, gender, and non-modulation. A sexual dimorphism in essential hypertension.
Hypertension 1997;29(4):980-5.
1997: Tao Q F; Hollenberg N K; Price D A; Graves S W
Sodium pump isoform specificity for the digitalis-like factor isolated from human peritoneal dialysate.
Hypertension 1997;29(3):815-21.
1997: Hollenberg N K; Martinez G; McCullough M; Meinking T; Passan D; Preston M; Rivera A; Taplin D; Vicaria-Clement M
Aging, acculturation, salt intake, and hypertension in the Kuna of Panama.
Hypertension 1997;29(1 Pt 2):171-6.
1996: Williams G H; Hollenberg N K; Hopkins P M; Jeunemaitre X
The role of intermediate phenotypes in essential hypertension: non-modulation as a model.
Endocrine research 1996;22(4):675-80.
1996: Hollenberg N K
Genes, hypertension, and intermediate phenotypes.
Current opinion in cardiology 1996;11(5):457-63.
1996: Krep H; Lefurgey A; Graves S W; Hockett D; Ingram P; Hollenberg N K
Elemental composition of Na pump inhibited rabbit aorta VSM cells by electron probe X-ray microanalysis.
The American journal of physiology 1996;271(2 Pt 2):H514-20.
1996: Tao Q F; Soszynski P A; Hollenberg N K; Graves S W
Specificity of the volume-sensitive sodium pump inhibitor isolated from human peritoneal dialysate in chronic renal failure.
Kidney international 1996;49(2):420-9.
1996: Moore T J; Rich G; McKnight J A; McCullough M; Hollenberg N K
Salt sensitivity of hypertension and responses to angiotensin converting enzyme inhibition with benazepril.
American journal of hypertension 1996;9(1):54-60.
1996: Krep H H; Graves S W; Price D A; Lazarus M; Ensign A; Soszynski P A; Hollenberg N K
Reversal of sodium pump inhibitor induced vascular smooth muscle contraction with digibind. Stoichiometry and its implications.
American journal of hypertension 1996;9(1):39-46.
1996: Hollenberg N K; Graves S W
Endogenous sodium pump inhibition: current status and therapeutic opportunities.
Progress in drug research. Fortschritte der Arzneimittelforschung. Progrès des recherches pharmaceutiques 1996;46():9-42.
1995: Hollenberg N K; Fisher N D
Renal circulation and blockade of the renin-angiotensin system. Is angiotensin-converting enzyme inhibition the last word?
Hypertension 1995;26(4):602-9.
1995: Krep H; Price D A; Soszynski P; Tao Q F; Graves S W; Hollenberg N K
Volume sensitive hypertension and the digoxin-like factor. Reversal by a Fab directed against digoxin in DOCA-salt hypertensive rats.
American journal of hypertension 1995;8(9):921-7.
1995: Gaboury C L; Hollenberg N K; Hopkins P N; Williams R; Williams G H
Metabolic derangements in nonmodulating hypertension.
American journal of hypertension 1995;8(9):870-5.
1995: Tao Q F; Soszynski P A; Hollenberg N K; Graves S W
A sensitive [Na,K]ATPase assay specific for inhibitors acting through the digitalis-binding site.
Journal of cardiovascular pharmacology 1995;25(6):859-63.
1995: Fisher N D; Allan D R; Gaboury C L; Hollenberg N K
Intrarenal angiotensin II formation in humans. Evidence from renin inhibition.
Hypertension 1995;25(5):935-9.
1995: Fisher N D; Hollenberg N
Renal vascular responses to renin inhibition with zankiren in men.
Clinical pharmacology and therapeutics 1995;57(3):342-8.
1995: Hollenberg N K; Graves S W
Koch's postulates and the digitalis-like factor.
Hypertension research : official journal of the Japanese Society of Hypertension 1995;18(1):1-6.
1994: Gaboury C L; Simonson D C; Seely E W; Hollenberg N K; Williams G H
Relation of pressor responsiveness to angiotensin II and insulin resistance in hypertension.
The Journal of clinical investigation 1994;94(6):2295-300.
1994: Glatter K A; Graves S W; Hollenberg N K; Soszynski P A; Tao Q F; Frem G J; Williams G H; Lazarus J M
Sustained volume expansion and [Na,K]ATPase inhibition in chronic renal failure.
American journal of hypertension 1994;7(11):1016-25.
1994: Allan D R; McKnight J A; Kifor I; Coletti C M; Hollenberg N K
Converting enzyme inhibition and renal tissue angiotensin II in the rat.
Hypertension 1994;24(4):516-22.
1994: Gordon M S; Gordon M B; Hollenberg N K; Williams G H
Nonmodulating trait may precede the development of hypertension.
American journal of hypertension 1994;7(9 Pt 1):789-93.
1994: Hollenberg N K; Moore T J
Age and the renal blood supply: renal vascular responses to angiotensin converting enzyme inhibition in healthy humans.
Journal of the American Geriatrics Society 1994;42(8):805-8.
1994: Tao Q F; Soszynski P A; Hollenberg N K; Graves S W
Sensitive assay for sodium pump inhibition.
Clinical chemistry 1994;40(8):1595-6.
1994: Fisher N D; Gleason R E; Moore T J; Williams G H; Hollenberg N K
Regulation of aldosterone secretion in hypertensive blacks.
Hypertension 1994;23(2):179-84.
1994: Fisher N D; Allan D; Kifor I; Gaboury C L; Williams G H; Moore T J; Hollenberg N K
Responses to converting enzyme and renin inhibition. Role of angiotensin II in humans.
Hypertension 1994;23(1):44-51.
1993: Stewart L; Hamilton C; Ingwall J; Naomi S; Graves S; Canessa M; Williams G; Hollenberg N
Vascular smooth muscle response to ouabain. Relation of tissue Na+ to the contractile response.
Circulation research 1993;73(6):1113-20.
1993: Conlin P R; Moore T J; Williams G H; Hollenberg N K
Rapid modulation of renal and adrenal responsiveness to angiotensin II.
Hypertension 1993;22(6):832-8.
1993: Hollenberg N K; Raij L
Angiotensin-converting enzyme inhibition and renal protection. An assessment of implications for therapy.
Archives of internal medicine 1993;153(21):2426-35.
1993: Graves S W; Glatter K A; Lazarus J M; Williams G H; Hollenberg N K
Volume expansion in renal failure patients: a paradigm for a clinically relevant [Na,K]ATPase inhibitor.
Journal of cardiovascular pharmacology 1993;22 Suppl 2():S54-7.
1992: Williams G H; Dluhy R G; Lifton R P; Moore T J; Gleason R; Williams R; Hunt S C; Hopkins P N; Hollenberg N K
Non-modulation as an intermediate phenotype in essential hypertension.
Hypertension 1992;20(6):788-96.
1992: Conlin P R; Braley L M; Menachery A I; Hollenberg N K; Williams G H
Abnormal norepinephrine and aldosterone responses to upright posture in nonmodulating hypertension.
The Journal of clinical endocrinology and metabolism 1992;75(4):1017-21.
1992: Hollenberg N K
Evolution of the treatment of hypertension: what really matters in the 1990s?
The American journal of medicine 1992;93(2A):4S-10S.
1992: Janicek M J; Meyerovitz M; Harrington D P; Hollenberg N K
Arterial response to ketanserin and aspirin in patients with advanced peripheral atherosclerosis.
Investigative radiology 1992;27(6):415-21.
1992: Paskins-Hurlburt A J; Hollenberg N K
"Tissue need" and limb collateral arterial growth. Skeletal contractile power and perfusion during collateral development in the rat.
Circulation research 1992;70(3):546-53.
1992: Gordon M S; Williams G H; Hollenberg N K
Renal and adrenal responsiveness to angiotensin II: influence of beta adrenergic blockade.
Endocrine research 1992;18(2):115-31.
1992: Hollenberg N K
Treatment of hypertension: the place of angiotensin-converting enzyme inhibitors in the nineties.
Journal of cardiovascular pharmacology 1992;20 Suppl 10():S29-32.
1991: Williams G H; Hollenberg N K
Functional derangements in the regulation of aldosterone secretion in hypertension.
Hypertension 1991;18(5 Suppl):III143-9.
1991: Naomi S; Graves S; Lazarus M; Williams G H; Hollenberg N K
Variation in apparent serum digitalis-like factor levels with different digoxin antibodies. The "immunochemical fingerprint".
American journal of hypertension 1991;4(10 Pt 1):795-801.
1991: Janicek M J; Van den Abbeele A D; DeSisto W C; Kassis A I; Holman B L; Tumeh S S; Hollenberg N K
Embolization of platelets after endothelial injury to the aorta in rabbits. Assessment with 111indium-labeled platelets and angiography.
Investigative radiology 1991;26(7):655-9.
1991: Hollenberg N K
Matitudinal elements and cardiovascular risk.
American journal of hypertension 1991;4(7 Pt 2):393S-395S.
1991: Williams G H; Moore T J; Hollenberg N K
Dysregulation of aldosterone secretion and its relationship to the pathogenesis of essential hypertension.
Endocrinology and metabolism clinics of North America 1991;20(2):423-47.
1991: Cordero P; Fisher N D; Moore T J; Gleason R; Williams G H; Hollenberg N K
Renal and endocrine responses to a renin inhibitor, enalkiren, in normal humans.
Hypertension 1991;17(4):510-6.
1991: Hollenberg N K
Management of hypertension and cardiovascular risk.
The American journal of medicine 1991;90(2A):2S-6S.
1991: Williams G H; Hollenberg N K
Non-modulating hypertension. A subset of sodium-sensitive hypertension.
Hypertension 1991;17(1 Suppl):I81-5.
1991: Blackshear J L; Orlandi C; Hollenberg N K
Constrictive effect of serotonin on visible renal arteries: a pharmacoangiographic study in anesthetized dogs.
Journal of cardiovascular pharmacology 1991;17(1):68-73.
1991: Hollenberg N K; Rodicio J L
The kidney in hypertension: treatment strategies.
Journal of cardiovascular pharmacology 1991;18 Suppl 4():S57-61.
1991: Hollenberg N K
Implications of thrombosis and vasospasm in peripheral vascular disease.
Journal of cardiovascular pharmacology 1991;17 Suppl 5():S21-8.
1990: Janicek M J; Van den Abbeele A D; Hollenberg N K; Kassis A I; Holman B L; Tumeh S S
Platelet activation and aggregation after endothelial injury. Assessment with indium-111-labeled platelets and angiography.
Investigative radiology 1990;25(9):988-93.
1990: Williams G H; Gordon M S; Stuenkel C A; Conlin P R; Hollenberg N K
Dopamine and nonmodulating hypertension.
American journal of hypertension 1990;3(6 Pt 2):112S-115S.
1990: Janicek M; Grassi C J; Meyerovitz M; Callahan M B; Sandor T; Whittemore A; Mannick J; Harrington D P; Hollenberg N K
Atherosclerosis, peripheral arterial disease and the vascular response to ketanserin.
Investigative radiology 1990;25(5):495-503.
1990: Rogacz S; Williams G H; Hollenberg N K
Time course of enhanced adrenal responsiveness to angiotensin on a low salt diet.
Hypertension 1990;15(4):376-80.
1990: Hollenberg N K
Management of hypertension: considerations involving cardiovascular risk reduction.
Journal of cardiovascular pharmacology 1990;15 Suppl 5():S73-8.
1990: Hollenberg N K; Nie Q
The effect of naftidrofuryl, a 5-HT2 antagonist, on collateral vascular responses to serotonin and to platelet activation.
Journal of cardiovascular pharmacology 1990;16 Suppl 3():S36-9.
1989: Williams G H; Hollenberg N K
Sodium-sensitive essential hypertension: emerging insights into an old entity.
Journal of the American College of Nutrition 1989;8(6):490-4.
1989: Hollenberg N K; Williams G H
Sodium-sensitive hypertension. Implications of pathogenesis for therapy.
American journal of hypertension 1989;2(10):809-15.
1989: Gordon M S; Steunkel C A; Conlin P R; Hollenberg N K; Williams G H
The role of dopamine in nonmodulating hypertension.
The Journal of clinical endocrinology and metabolism 1989;69(2):426-32.
1989: Hollenberg N K; Sandor T; Holtzman E; Meyerovitz M F; Harrington D P
Renal vasomotion in essential hypertension: influence of vasodilators.
Hypertension 1989;14(1):9-13.
1989: Lifton R P; Hopkins P N; Williams R R; Hollenberg N K; Williams G H; Dluhy R G
Evidence for heritability of non-modulating essential hypertension.
Hypertension 1989;13(6 Pt 2):884-9.
1989: Hollenberg N K; Mickiewicz C
Hyperkalemia in diabetes mellitus. Effect of a triamterene-hydrochlorothiazide combination.
Archives of internal medicine 1989;149(6):1327-30.
1989: Seely E W; LeBoff M S; Brown E M; Chen C; Posillico J T; Hollenberg N K; Williams G H
The calcium channel blocker diltiazem lowers serum parathyroid hormone levels in vivo and in vitro.
The Journal of clinical endocrinology and metabolism 1989;68(6):1007-12.
1989: Redgrave J; Canessa M; Gleason R; Hollenberg N K; Williams G H
Red blood cell lithium-sodium countertransport in non-modulating essential hypertension.
Hypertension 1989;13(6 Pt 2):721-6.
1989: Holtzman E; Braley L M; Menachery A; Williams G H; Hollenberg N K
Rate of activation of renin-angiotensin-aldosterone axis and sodium intake in rats.
The American journal of physiology 1989;256(5 Pt 2):H1311-5.
1989: Dluhy R G; Smith K; Taylor T; Hollenberg N K; Williams G H
Prolonged converting enzyme inhibition in non-modulating hypertension.
Hypertension 1989;13(4):371-7.
1989: Hollenberg N K; Mickiewicz C W
Postmarketing surveillance in 70,898 patients treated with a triamterene/hydrochlorothiazide combination (Maxzide)
The American journal of cardiology 1989;63(4):37B-41B.
1989: Seely E W; Moore T J; Rogacz S; Gordon M S; Gleason R E; Hollenberg N K; Williams G H
Angiotensin-mediated renin suppression is altered in non-modulating hypertension.
Hypertension 1989;13(1):31-7.
1988: Hollenberg N K; Williams G H
Sodium sensitive hypertension: renal and adrenal non-modulation in its pathogenesis.
The Kidney 1988;21(3):13-8.
1988: Hollenberg N K
Medical therapy for renovascular hypertension: a review.
American journal of hypertension 1988;1(4 Pt 2):338S-343S.
1988: Hollenberg N K
Control of renal perfusion and function in congestive heart failure.
The American journal of cardiology 1988;62(8):72E-75E.
1988: Hollenberg N
Serotonin, atherosclerosis, and collateral vessel spasm.
American journal of hypertension 1988;1(3 Pt 3):312S-316S.
1988: Holtzman E J; Braley L M; Williams G H; Hollenberg N K
Kinetics of sodium homeostasis in rats: rapid excretion and equilibration rates.
The American journal of physiology 1988;254(6 Pt 2):R1001-6.
1988: Hollenberg N K
Successful behavior changes in a man with hypertension.
Cardiovascular reviews & reports 1988;9(5):30-1.
1988: Hollenberg N K
Experience, progress, and clinical perspectives on angiotensin converting enzyme inhibition.
The American journal of medicine 1988;84(4A):1-3.
1988: Hollenberg N K
Renal perfusion and function. The implications of converting enzyme inhibition.
The American journal of medicine 1988;84(4A):9-15.
1988: Hollenberg N K; Monteiro K; Sandor T
Endothelial injury provokes collateral arterial vasoconstriction: response to a serotonin 2 antagonist, thromboxane antagonist or synthetase inhibition.
The Journal of pharmacology and experimental therapeutics 1988;244(3):1164-8.
1988: Hollenberg N K
Angiotensin converting enzyme inhibition and the kidney.
Current opinion in cardiology 1988;3(Suppl 1):S19-29.
1988: Dluhy R G; Hopkins P; Hollenberg N K; Williams G H; Williams R R
Heritable abnormalities of the renin-angiotensin-aldosterone system in essential hypertension.
Journal of cardiovascular pharmacology 1988;12 Suppl 3():S149-54.
1987: Hollenberg N K
Vasodilators, antihypertensive therapy and the kidney.
The American journal of cardiology 1987;60(17):57I-60I.
1987: Rabinowe S L; Redgrave J E; Shoback D M; Podolsky S; Hollenberg N K; Williams G H
Renin suppression by saline is blunted in nonmodulating essential hypertension.
Hypertension 1987;10(4):404-8.
1987: Hollenberg N K
Hypertension and the kidney: implications of the kidney for effective antihypertensive therapy
Medicographia 1987;9(3):2-4.
1987: Hollenberg N K
Collateral arterial tree and responses to serotonin.
Journal of cardiovascular pharmacology 1987;10 Suppl 3():S35-8.
1986: Guidi E; Hollenberg N K
Different reactivity to angiotensin II of peripheral and renal arteries in spontaneously hypertensive rats: effect of acute and chronic angiotensin converting enzyme inhibition.
Journal of hypertension. Supplement : official journal of the International Society of Hypertension 1986;4(6):S480-2.
1986: Hollenberg N K; Moore T; Shoback D; Redgrave J; Rabinowe S; Williams G H
Abnormal renal sodium handling in essential hypertension. Relation to failure of renal and adrenal modulation of responses to angiotensin II.
The American journal of medicine 1986;81(3):412-8.
1985: Redgrave J; Rabinowe S; Hollenberg N K; Williams G H
Correction of abnormal renal blood flow response to angiotensin II by converting enzyme inhibition in essential hypertensives.
The Journal of clinical investigation 1985;75(4):1285-90.
1984: Koletsky R J; Gordon M B; LeBoff M S; Moore T J; Dluhy R G; Hollenberg N K; Williams G H
Captopril enhances vascular and adrenal responsiveness to angiotensin II in essential hypertension.
Clinical science (London, England : 1979) 1984;66(3):299-305.
1983: Shoback D M; Williams G H; Moore T J; Dluhy R G; Podolsky S; Hollenberg N K
Defect in the sodium-modulated tissue responsiveness to angiotensin II in essential hypertension.
The Journal of clinical investigation 1983;72(6):2115-24.
1983: Shoback D M; Williams G H; Swartz S L; Davies R O; Hollenberg N K
Time course and effect of sodium intake on vascular and hormonal responses to enalapril (MK 421) in normal subjects.
Journal of cardiovascular pharmacology 1983;5(6):1010-8.
1983: Shoback D M; Williams G H; Hollenberg N K; Davies R O; Moore T J; Dluhy R G
Endogenous angiotensin II as a determinant of sodium-modulated changes in tissue responsiveness to angiotensin II in normal man.
The Journal of clinical endocrinology and metabolism 1983;57(4):764-70.
1982: LeBoff M s; Dluhy R G; Hollenberg N K; Moore T J; Koletsky R J; Williams G H
Abnormal renin short feedback loop in essential hypertension is reversible with converting enzyme inhibition.
The Journal of clinical investigation 1982;70(2):335-41.
1981: Moore T J; Crantz F R; Hollenberg N K; Koletsky R J; Leboff M S; Swartz S L; Levine L; Podolsky S; Dluhy R G; Williams G H
Contribution of prostaglandins to the antihypertensive action of captopril in essential hypertension.
Hypertension 1981;3(2):168-73.
1980: Swartz S L; Williams G H; Hollenberg N K; Crantz F R; Levine L; Moore T J; Dluhy R G
Increase in prostaglandins during converting enzyme inhibition.
Clinical science (London, England : 1979) 1980;59 Suppl 6():133s-135s.
1980: Swartz S L; Williams G H; Hollenberg N K; Crantz F R; Moore T J; Levine L; Sasahara A A; Dluhy R G
Endocrine profile in the long-term phase of converting-enzyme inhibition.
Clinical pharmacology and therapeutics 1980;28(4):499-508.
1980: Crantz F R; Swartz S L; Hollenberg N K; Moore T J; Dluhy R G; Williams G H
Differences in response to the peptidyldipeptide hydrolase inhibitors SQ 20,881 and SQ 14,225 in normal-renin essential hypertension.
Hypertension 1980;2(5):604-9.

Sign-in to see more